Evidence map›Paper›PMID 42836010›Full record

ArticleBiomedical reports2026

Nrf2 and PGC-1α signaling in temozolomide resistance in glioblastoma under hypoxia.

Pinpat Tripatara, Tasanee Onkoksoong, Sunisa Prasopporn, Sith Sathornsumetee, Siwanon Jirawatnotai, Uraiwan Panich

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pinpat TripataraDepartment of Pharmacology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Tasanee OnkoksoongDepartment of Pharmacology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Sunisa PrasoppornDepartment of Pharmacology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Sith SathornsumeteeDepartment of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Siwanon JirawatnotaiDepartment of Pharmacology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Uraiwan PanichDepartment of Pharmacology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypoxia is a key contributor to chemoresistance in glioblastoma (GBM), partly through the activation of nuclear factor erythroid 2-related factor 2 (Nrf2)-dependent cellular stress responses and mitochondrial adaptive programs. The present study investigated Nrf2 signaling in hypoxia-associated resistance to temozolomide (TMZ) in U87MG cells, a glioblastoma cell line, and evaluated whether pharmacological suppression of Nrf2 pathway output with brusatol enhances TMZ sensitivity under hypoxic conditions. U87MG cells were cultured under normoxic or hypoxic conditions (1% O

Indexed as

brusatolchemoresistanceglioblastomahypoxianuclear factor erythroid 2-related factor 2peroxisome proliferator-activated receptor γcoactivator 1 α

Identifiers

PMID42836010
PMCPMC13636387

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.